Only about half of breast cancer cases can be explained by known risk factors, hampering prevention efforts. Breast density is a strong risk factor, and recent evidence indicates that assessing changes in density may be more accurate for predicting future breast cancer.
AYAs with HMs have treatment plans and side effects that interrupt typical developmental processes. These barriers may impact their mental well-being and their overall quality of life.
Many AYAs with breast cancer may struggle to find the information and support they need. These challenges can be even greater for AYAs who face extra barriers because of unfair social conditions.
HRD testing is an effective biomarker test for the treatment management for advanced ovarian cancer. Currently, HRD testing is not funded publicly for all individuals in Canada.
Primary central nervous system (CNS) tumors are the second most common pediatric cancer and the leading cause of cancer related deaths in this population.
BC Cancer Foundation is the fundraising partner of BC Cancer, which includes BC Cancer Research. Together with our donors, we are changing cancer outcomes for British Columbians by funding innovative research and personalized treatment and care.
